Brief: Asit Biotech Operating Loss At 30 June 2018 Narrows To 5.4 Million Euros

European Medical Solutions SA

19/09/2018 06:29

Sept 19 (Reuters) - ASIT BIOTECH SA  ASIT.BR :
    * ASIT BIOTECH PRESENTS ITS 2018 HALF-YEAR RESULTS AND PROVIDES AN UPDATE ON ITS CLINICAL
PROGRAMS
UNTIL END-2019
    * CASH POSITION AT 30 JUNE 2018 OF EUR 13.5 MILLION
    * CLINICAL AND RESEARCH AND DEVELOPMENT PROGRAMS ON TRACK WITH MULTIPLE DEVELOPMENT
MILESTONES BY
END-2019
    * OPERATING LOSS (EUR 5.4 MILLION AT 30 JUNE 2018 VERSUS 6.8 MILLION AT 30 JUNE 2017)
    * FIRST-IN-MAN CLINICAL STUDIES OF HDM-ASIT+ FOR HOUSE DUST MITE RHINITIS AND OF PNT-ASIT+
FOR
PEANUT ALLERGY PLANNED IN H2 2019
    * H1 NET LOSS EUR  5.4 MILLION VERSUS LOSS OF EUR 6.8 MILLION YEAR AGO
    * P-ASIT+ - PREPARATION OF EUROPEAN CONFIRMATORY PHASE III STUDY IN ADULTS (ABT-011) IS
UNDERWAY
WITH SCREENING OF PATIENTS EXPECTED TO START EARLY 2019 AND FIRST-PATIENT FIRST-VISIT PLANNED IN
Q1 2019
    * DISCUSSIONS WITH FDA ARE ONGOING TO DEFINE CLINICAL DEVELOPMENT OF GP-ASIT+ IN U.S. THAT
SHOULD
MOST PROBABLY START AFTER COMPLETION OF ABT-011 STUDY

Source text for Eikon:  ID:nBw5CW1SSa 
Further company coverage:  ASIT.BR 

 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))